Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 15/20 | 0.51 |
| ▸ | PPARA | Q07869 | 12/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5376864 | 0.99 | FFAR1 (0.55) | FFAR1PPARGPPARAKDRMEN1 | |
| SCHEMBL5377223 | 0.93 | FFAR1 (0.51) | FFAR1PPARGPPARAKDR | |
| SCHEMBL4847694 | 0.92 | KDR (0.57) | FFAR1PPARGPPARAKDR | |
| SCHEMBL4849050 | 0.90 | FFAR1 (0.43) | FFAR1PPARGPPARAMEN1HSP90AA1 | |
| SCHEMBL5385889 | 0.89 | FFAR1 (0.57) | FFAR1PPARGPPARAKDR | |
| SCHEMBL4850889 | 0.88 | FFAR1 (0.42) | FFAR1PPARGPPARAKDRMEN1 | |
| SCHEMBL5381940 | 0.87 | FFAR1 (0.41) | FFAR1PPARGPPARAMEN1HSP90AA1 | |
| SCHEMBL5372048 | 0.87 | MEN1 (0.51) | MEN1HSP90AA1KMT2A | |
| SCHEMBL5376925 | 0.86 | MAPT (0.44) | FFAR1PPARGPPARAKDR | |
| SCHEMBL5380604 | 0.86 | FFAR1 (0.56) | FFAR1PPARGPPARAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368578-B2 | Five-membered heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20060135578-A1 | Five-membered heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1541564-A1 | FIVE-MEMBERED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135578-A1 | Five-membered heterocyclic compounds | GPR119, OR10J3, CYP11B1 | FFAR1 771/4885PPARG 536/4885PPARA 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.